SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

Aligos Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value, $0.0001 per share

(Title of Class of Securities)

01626L204

(CUSIP Number)

Lawrence M. Blatt, Ph.D.
One Corporate Dr., 2nd Floor
South San Francisco, CA, 94080
(800) 466-6059

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/16/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

01626L204

Name of reporting person

Lawrence M. Blatt

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 316,228.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 316,228.00
10	Shared Dispositive Power 0.00

Aggregate amount beneficially owned by each reporting person

316,228.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

5.6 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, par value, $0.0001 per share

(b)

Name of Issuer:

Aligos Therapeutics, Inc.

(c)

Address of Issuer's Principal Executive Offices:

One Corporate Drive, 2nd Floor, South San Francisco, CALIFORNIA , 94080.

Item 2.

Identity and Background

(a)

The Schedule 13D is being filed by Lawrence M. Blatt, Ph.D. (the "Reporting Person").

(b)

The business address of the Reporting Person is c/o Aligos Therapeutics, Inc., One Corporate Drive, 2nd Floor, South San Francisco, CA 94080.

(c)

The Reporting Person's present principal occupation is Chair, President and Chief Executive Officer of the Issuer.

(d)

During the last five years, the Reporting Person has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

The Reporting Person is a citizen of the United States.

Item 3.

Source and Amount of Funds or Other Consideration

The Reporting Person acquired (approximately on a post-split basis) (i) 10,922 shares of Common Stock acquired indirectly by certain entities in connection with the conversion of preferred stock on October 20, 2020, in connection with the Issuer's initial public offering, and (ii) 24,411 shares of Common Stock and warrants exercisable for 12,206 shares of Common Stock for cash consideration of $499,999.95 in a private placement from the Issuer on October 25, 2023. The remaining shares of Common Stock were acquired by the Reporting Person as compensation by the Issuer in consideration for services rendered to the Issuer.

Item 4.

Purpose of Transaction

General The Reporting Person intends to review his investments in the Issuer on a continuing basis. Any actions the Reporting Person might undertake will be dependent upon the Reporting Person's review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments. The Reporting Person may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. The Reporting Person may also enter into financial instruments or other agreements with institutional or other counterparties that would increase or decrease the Reporting Person's economic exposure with respect to their investment in the Issuer, which instruments or agreements may or may not affect the Reporting Person's beneficial ownership in securities of the Issuer. In addition, the Reporting Person, in his positions as President, Chief Executive Officer and a director of the Issuer, may engage in discussions with management, the Issuer's board of directors (the "Board"), other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Common Stock; security offerings and/or stock repurchases by the Issuer; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board. To facilitate their consideration of such matters, the Reporting Person may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Person may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Person will likely take some or all of the foregoing steps at preliminary stages in their consideration of various possible courses of action before forming any intention to pursue any particular plan or direction. Other than as described above, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Person may change his purpose or formulate different plans or proposals with respect thereto at any time.

Item 5.

Interest in Securities of the Issuer

(a)

The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of June 16, 2026, based upon 5,388,223 shares of voting Common Stock outstanding as of May 1, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2026. The Reporting Person is the beneficial owner of 316,228 shares of Common Stock, which consist of (i) 3,251 shares of Common Stock held directly by the Reporting Person, (ii) 78,781 shares of Common Stock held by the Lawrence M. Blatt Living Trust dated 8/27/2014, (iii) 4,904 shares of Common Stock held by PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA, (iv) 740 shares of Common Stock held by Zachary David Blatt Irrevocable Trust dated 8/24/2014, (v) 740 shares of Common Stock held by Zoe Anne Blatt Irrevocable Trust dated 8/24/2014, (vi) 12,206 shares of common stock held by exercisable warrants and (vii) 215,606 shares of Common Stock underlying stock options held directly by the Reporting Person that are currently exercisable or may be exercised within 60 days of June 16, 2026. The shares beneficially owned by the Reporting Person consistutes approximately 5.6% of the voting shares outstanding.

(b)

Sole power to vote or direct the vote: 316,228 Shared power to vote: 0 Sole power to dispose or direct the disposition of: 316,228 Shared power to dispose or direct the disposition of: 0

(c)

During the past 60 days, the Reporting Person has not effected any transactions with respect to the Common Stock.

(d)

None.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Except as set forth herein, the Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

Item 7.

Material to be Filed as Exhibits.

None.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lawrence M. Blatt

Signature:	/s/ Lawrence M. Blatt
Name/Title:	Lawrence M. Blatt, Ph.D.
Date:	06/24/2026

SEC Form SCHEDULE 13D filed by Aligos Therapeutics Inc.